WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...

CMB International Securities analyst Jill Wu has maintained their bullish stance on WXIBF stock, giving a Buy rating on January 13.Stay Ahead ...

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

The employees at WuXi Biologics have once again shown their commitment to the local community with their fourth annual ...

SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

A proposed sale to a larger credit union is being put before the Dundalk District Credit Union membership for a decision in two weeks’ time. The annual general and special meeting is to take ...

The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.